{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:00:56Z","timestamp":1791640856216,"version":"4.3.4"},"reference-count":41,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Immunoassays using the interaction between streptavidin and biotin are used for clinical chemical analytes on platforms by many different manufacturers. The design can be susceptible to interference from high-dose biotin intake in patients, which remains an often-overlooked confounder despite recently increased awareness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To evaluate an easily implementable method of in vitro biotin depletion for the removal of biotin interference in immunoassays for potentially time-critical analytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>A biotin stock solution was made and de-identified patient samples were spiked to reach a biotin concentration of 1.126 \u00d7 106 pg\/mL, the maximum reported biotin concentration 1 to 2 hours after a single oral dose of 300 mg biotin. Then, the resulting interference in Elecsys immunoassays for cortisol, cyclosporine A, tacrolimus, digitoxin, thyroid-stimulating hormone, free triiodothyronine, free thyroxine, C-peptide, insulin, N-terminal pro-B\u2013type natriuretic peptide, troponin T high sensitive, human immunodeficiency virus, procalcitonin, \u03b2 human chorionic gonadotropin, toxoplasma immunoglobulin M, and toxoplasma immunoglobulin G was evaluated before and after biotin depletion using streptavidin particles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>All tested immunoassays, with the exception of toxoplasma immunoglobulin M and toxoplasma immunoglobulin G, suffered from significant biotin interference. The depletion protocol removed assay interference due to biotin and produced results that were close or identical to initial prespike measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Despite an increase in turnaround times, biotin adsorption is a feasible countermeasure for biotin interference in Elecsys immunoassays. Until test kits with an increased resistance to the interference from high-dose biotin intake are distributed, the evaluated protocol can provide results properly reflecting the patient's clinical condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2019-0425-oa","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T12:13:45Z","timestamp":1579176825000},"page":"1108-1117","source":"Crossref","is-referenced-by-count":21,"title":["Interference From High-Dose Biotin Intake in Immunoassays for Potentially Time-Critical Analytes by Roche"],"prefix":"10.5858","volume":"144","author":[{"given":"Ingo","family":"Mrosewski","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, MDI Limbach Berlin GmbH, Berlin, Germany (Mrosewski, Switkowski, Urbank)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Urbank","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, MDI Limbach Berlin GmbH, Berlin, Germany (Mrosewski, Switkowski, Urbank)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stauch","sequence":"additional","affiliation":[{"name":"Department of Toxicology, MVZ Labor PD Dr. Volkmann und Kollegen GbR, Karlsruhe, Germany (Stauch)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Switkowski","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, MDI Limbach Berlin GmbH, Berlin, Germany (Mrosewski, Switkowski, Urbank)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"2020090814512528900_i1543-2165-144-9-1108-b01","doi-asserted-by":"crossref","unstructured":"Ostrowska\n              M,\n            \n            \n              Bartoszewicz\n              Z,\n            \n            \n              Bednarczuk\n              T,\n            \n            \n              Walczak\n              K,\n            \n            \n              Zgliczynski\n              W,\n            \n            \n              Glinicki\n              P.\n            \n          \n          The effect of biotin interference on the results of blood hormone assays.\n\t\t\t\t\tEndokrynol Pol.\n\t\t\t\t\t2019;\n\t\t\t\t\t70(1):\n\t\t\t\t\t102\u2013\n\t\t\t\t\t121.","DOI":"10.5603\/EP.a2018.0084"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b02","doi-asserted-by":"crossref","unstructured":"Trambas\n              C,\n            \n            \n              Zhong\n              L,\n            \n            \n              Yen\n              T,\n            \n            \n              Sikaris\n              K.\n            \n          \n          Characterization of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays.\n\t\t\t\t\tAnn Clin Biochem.\n\t\t\t\t\t2018;\n\t\t\t\t\t55(2):\n\t\t\t\t\t205\u2013\n\t\t\t\t\t215.","DOI":"10.1177\/0004563217701777"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b03","doi-asserted-by":"crossref","unstructured":"Piketty\n              ML,\n            \n            \n              Polak\n              M,\n            \n            \n              Flechtner\n              I,\n            \n            \n              Gonzales-Brice\u00f1o\n              L,\n            \n            \n              Souberbielle\n              JC.\n            \n          \n          False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences.\n\t\t\t\t\tClin Chem Lab Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t55(6):\n\t\t\t\t\t780\u2013\n\t\t\t\t\t788.","DOI":"10.1515\/cclm-2016-0606"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b04","doi-asserted-by":"crossref","unstructured":"Piketty\n              ML,\n            \n            \n              Prie\n              D,\n            \n            \n              Sedel\n              F,\n            \n            et al.\n          \n          High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference.\n\t\t\t\t\tClin Chem Lab Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t55(6):\n\t\t\t\t\t817\u2013\n\t\t\t\t\t825.","DOI":"10.1515\/cclm-2016-1183"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b05","unstructured":"Gifford\n              JL,\n            \n            \n              Sadrzadeh\n              SMH,\n            \n            \n              Naugler\n              C.\n            \n          \n          Biotin interference: underrecognized patient safety risk in laboratory testing.\n\t\t\t\t\tCan Fam Physician.\n\t\t\t\t\t2018;\n\t\t\t\t\t64(5):\n\t\t\t\t\t370."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b06","unstructured":"Hauptmann\n              M,\n            \n            \n              Jaraskweski\n              J,\n            \n            \n              Schneider\n              R.\n            \n          \n          Evaluation of biotin interference on the Abbott Architect assays.\n\t\t\t\t\tPaper presented at:American Association for Clinical Chemistry Annual Meeting; July 30\u2013August 3, 2017; San Diego, CA.\n\t\t\t\t\thttps:\/\/www.scribd.com\/document\/400719310\/Evaluation-of-Biotin-Interference. Accessed September 16, 2019."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b07","doi-asserted-by":"crossref","unstructured":"Mrosewski\n              I,\n            \n            \n              Neumann\n              I,\n            \n            \n              Switkowski\n              R.\n            \n          \n          Interference of high dose biotin supplementation with thyroid parameters in immunoassays utilizing the interaction between streptavidin and biotin: a case report and review of current literature.\n\t\t\t\t\tClin Lab.\n\t\t\t\t\t2019;\n\t\t\t\t\t65(1):\n\t\t\t\t\t165\u2013\n\t\t\t\t\t168.","DOI":"10.7754\/Clin.Lab.2018.180637"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b08","doi-asserted-by":"crossref","unstructured":"Chun\n              KY.\n            \n          \n          Biotin interference in diagnostic tests.\n\t\t\t\t\tClin Chem.\n\t\t\t\t\t2017;\n\t\t\t\t\t63(2):\n\t\t\t\t\t619\u2013\n\t\t\t\t\t620.","DOI":"10.1373\/clinchem.2016.267286"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b09","doi-asserted-by":"crossref","unstructured":"Donti\n              TR,\n            \n            \n              Blackburn\n              PR,\n            \n            \n              Atwal\n              PS.\n            \n          \n          Holocarboxylase synthetase deficiency pre and post newborn screening.\n\t\t\t\t\tMol Genet Metab Rep.\n\t\t\t\t\t2016;\n\t\t\t\t\t7:\n\t\t\t\t\t40\u2013\n\t\t\t\t\t44.","DOI":"10.1016\/j.ymgmr.2016.03.007"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b10","doi-asserted-by":"crossref","unstructured":"Navarro\n              PC,\n            \n            \n              Guerra\n              A,\n            \n            \n              Alvarez\n              JG,\n            \n            \n              Ortiz\n              FJ.\n            \n          \n          Cutaneous and neurologic manifestations of biotinidase deficiency.\n\t\t\t\t\tInt J Dermatol.\n\t\t\t\t\t2000;\n\t\t\t\t\t39(5):\n\t\t\t\t\t363\u2013\n\t\t\t\t\t365.","DOI":"10.1046\/j.1365-4362.2000.00841.x"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b11","doi-asserted-by":"crossref","unstructured":"Zeng\n              WQ,\n            \n            \n              Al-Yamani\n              E,\n            \n            \n              Acierno\n              JS\n              Jr\n            ,\n\t\t\t\t\t\tet al.\n          Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3.\n\t\t\t\t\tAm J Hum Genet.\n\t\t\t\t\t2005;\n\t\t\t\t\t77(1):\n\t\t\t\t\t16\u2013\n\t\t\t\t\t26.","DOI":"10.1086\/431216"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b12","doi-asserted-by":"crossref","unstructured":"Minkovsky\n              A,\n            \n            \n              Lee\n              MN,\n            \n            \n              Dowlatshahi\n              M,\n            \n            et al.\n          \n          High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays.\n\t\t\t\t\tAACE Clin Case Rep.\n\t\t\t\t\t2016;\n\t\t\t\t\t2(4):\n\t\t\t\t\t370\u2013\n\t\t\t\t\t373.","DOI":"10.4158\/EP161261.CR"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b13","doi-asserted-by":"crossref","unstructured":"Tourbah\n              A,\n            \n            \n              Lebrun-Frenay\n              C,\n            \n            \n              Edan\n              G,\n            \n            et al.\n          \n          MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomized, double-blind, placebo-controlled study.\n\t\t\t\t\tMult Scler.\n\t\t\t\t\t2016;\n\t\t\t\t\t22(13):\n\t\t\t\t\t1719\u2013\n\t\t\t\t\t1731.","DOI":"10.1177\/1352458516667568"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b14","doi-asserted-by":"crossref","unstructured":"Sedel\n              F,\n            \n            \n              Papeix\n              C,\n            \n            \n              Bellanger\n              A,\n            \n            et al.\n          \n          High doses of biotin in chronic progressive multiple sclerosis: a pilot study.\n\t\t\t\t\tMult Scler Relat Disord.\n\t\t\t\t\t2015;\n\t\t\t\t\t4(2):\n\t\t\t\t\t159\u2013\n\t\t\t\t\t169.","DOI":"10.1016\/j.msard.2015.01.005"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b15","doi-asserted-by":"crossref","unstructured":"McCarty\n              MF,\n            \n            \n              DiNicolantonio\n              JJ.\n            \n          \n          Neuroprotective potential of high-dose biotin.\n\t\t\t\t\tMed Hypotheses.\n\t\t\t\t\t2017;\n\t\t\t\t\t109:\n\t\t\t\t\t145\u2013\n\t\t\t\t\t149.","DOI":"10.1016\/j.mehy.2017.10.012"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b16","doi-asserted-by":"crossref","unstructured":"Trambas\n              CM,\n            \n            \n              Sikaris\n              KA,\n            \n            \n              Lu\n              ZX.\n            \n          \n          More on biotin treatment mimicking Graves' disease.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2016;\n\t\t\t\t\t375(17):\n\t\t\t\t\t1698.","DOI":"10.1056\/NEJMc1611875"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b17","doi-asserted-by":"crossref","unstructured":"Mock\n              DM.\n            \n          \n          Biotin: from nutrition to therapeutics.\n\t\t\t\t\tJ Nutr.\n\t\t\t\t\t2017;\n\t\t\t\t\t147(8):\n\t\t\t\t\t1487\u2013\n\t\t\t\t\t1492.","DOI":"10.3945\/jn.116.238956"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b18","doi-asserted-by":"crossref","unstructured":"Hemmati\n              M,\n            \n            \n              Babaei\n              H,\n            \n            \n              Abdolsalehei\n              M.\n            \n          \n          Survey of the effect of biotin on glycemic control and plasma lipid concentrations in type 1 diabetic patients in Kermanshah in Iran (2008\u20132009).\n\t\t\t\t\tOman Med J.\n\t\t\t\t\t2013;\n\t\t\t\t\t28(3):\n\t\t\t\t\t195\u2013\n\t\t\t\t\t198.","DOI":"10.5001\/omj.2013.53"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b19","doi-asserted-by":"crossref","unstructured":"Maebashi\n              M,\n            \n            \n              Makino\n              Y,\n            \n            \n              Furukawa\n              Y,\n            \n            et al.\n          \n          Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin-dependent diabetes mellitus.\n\t\t\t\t\tJ Clin Biochem Nutr.\n\t\t\t\t\t1993;\n\t\t\t\t\t14(3):\n\t\t\t\t\t211\u2013\n\t\t\t\t\t218.","DOI":"10.3164\/jcbn.14.211"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b20","doi-asserted-by":"crossref","unstructured":"McCarty\n              MF.\n            \n          \n          In type 1 diabetics, high-dose biotin may compensate for low hepatic insulin exposure, promoting a more normal expression of glycolytic and gluconeogenic enyzymes and thereby aiding glycemic control.\n\t\t\t\t\tMed Hypotheses.\n\t\t\t\t\t2016;\n\t\t\t\t\t95:\n\t\t\t\t\t45\u2013\n\t\t\t\t\t48.","DOI":"10.1016\/j.mehy.2016.08.002"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b21","doi-asserted-by":"crossref","unstructured":"Dakshinamurti\n              K.\n            \n          \n          Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes).\n\t\t\t\t\tCan J Physiol Pharmacol.\n\t\t\t\t\t2015;\n\t\t\t\t\t93(5):\n\t\t\t\t\t355\u2013\n\t\t\t\t\t362.","DOI":"10.1139\/cjpp-2014-0479"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b22","doi-asserted-by":"crossref","unstructured":"Mock\n              DM.\n            \n          \n          Adequate intake of biotin in pregnancy: why bother?\n          \n            J Nutr\n          .\n\t\t\t\t\t2014;\n\t\t\t\t\t144(12):\n\t\t\t\t\t1885\u2013\n\t\t\t\t\t1886.","DOI":"10.3945\/jn.114.203356"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b23","doi-asserted-by":"crossref","unstructured":"Holmes\n              EW,\n            \n            \n              Samarasinghe\n              S,\n            \n            \n              Emanuele\n              MA,\n            \n            \n              Meah\n              F.\n            \n          \n          Biotin interference in clinical immunoassays: a cause for concern.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t141(11):\n\t\t\t\t\t1459\u2013\n\t\t\t\t\t1460.","DOI":"10.5858\/arpa.2017-0107-LE"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b24","doi-asserted-by":"crossref","unstructured":"Katzman\n              BM,\n            \n            \n              Lueke\n              AJ,\n            \n            \n              Donato\n              LJ,\n            \n            \n              Jaffe\n              AS,\n            \n            \n              Baumann\n              NA.\n            \n          \n          Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department.\n\t\t\t\t\tClin Biochem.\n\t\t\t\t\t2018;\n\t\t\t\t\t60:\n\t\t\t\t\t11\u2013\n\t\t\t\t\t16.","DOI":"10.1016\/j.clinbiochem.2018.07.004"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b25","unstructured":"US Food and Drug Administration.\n          The FDA warns that biotin may interfere with lab tests: FDA safety communication.\n\t\t\t\t\thttps:\/\/www.fda.gov\/MedicalDevices\/Safety\/AlertsandNotices\/ucm586505.htm. Published November 28, 2017. Accessed September 17, 2019."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b26","unstructured":"Association for Clinical Biochemistry & Laboratory Medicine.\n          A statement from the ACB Scientific Committee regarding biotin \/ vitamin B7 interference in immunoassays issued July 2018.\n\t\t\t\t\thttp:\/\/www.acb.org.uk\/docs\/default-source\/documents\/statement-from-acb-scicom-biotin-oct2018-1. Accessed July 20, 2019."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b27","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte [Federal Institute for Drugs and Medical Devices].\n          Rote-Hand-Brief zu biotinhaltigen Arzneimitteln: Risiko falscher Ergebnisse von Laboruntersuchungen durch Biotininterferenzen.\n\t\t\t\t\thttps:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2019\/rhb-biotin.html. Published May 15, 2019. Accessed July 20, 2019."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b28","unstructured":"European Medicines Agency.\n          PRAC recommendations on signals.\n\t\t\t\t\thttps:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-14-17-january-2019-prac-meeting_en.pdf. Published February 2019. Accessed September 17, 2019."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b29","doi-asserted-by":"crossref","unstructured":"P\u00f6hler\n              A,\n            \n            \n              Faigle\n              J,\n            \n            \n              Staack\n              RF.\n            \n          \n          Evaluation of potential biotin interference in immunogenicity testing [published online May 9, 2019].\n\t\t\t\t\tBioanalysis.\n\t\t\t\t\t2019;\n\t\t\t\t\t11(17):\n\t\t\t\t\t1547\u2013\n\t\t\t\t\t1554.\n\t\t\t\t\tdoi:10.4155\/bio-2019-0080","DOI":"10.4155\/bio-2019-0080"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b30","doi-asserted-by":"crossref","unstructured":"Peyro Saint Paul\n              L,\n            \n            \n              Debruyne\n              D,\n            \n            \n              Bernard\n              D,\n            \n            \n              Mock\n              DM,\n            \n            \n              Defer\n              GL.\n            \n          \n          Pharmacokinetics and pharmacodynamics of MD1003 (high dose biotin) in the treatment of progressive multiple sclerosis.\n\t\t\t\t\tExpert Opin Drug Metab Toxicol.\n\t\t\t\t\t2016;\n\t\t\t\t\t12(3):\n\t\t\t\t\t327\u2013\n\t\t\t\t\t344.","DOI":"10.1517\/17425255.2016.1136288"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b31","doi-asserted-by":"crossref","unstructured":"Ross\n              DS,\n            \n            \n              Burch\n              HB,\n            \n            \n              Cooper\n              DS,\n            \n            et al.\n          \n          2016 Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis.\n\t\t\t\t\tThyroid.\n\t\t\t\t\t2016;\n\t\t\t\t\t26(10):\n\t\t\t\t\t1342\u2013\n\t\t\t\t\t1421.","DOI":"10.1089\/thy.2016.0229"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b32","doi-asserted-by":"crossref","unstructured":"Trambas\n              C,\n            \n            \n              Lu\n              Z,\n            \n            \n              Yen\n              T,\n            \n            \n              Sikaris\n              K.\n            \n          \n          Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays.\n\t\t\t\t\tAnn Clin Biochem.\n\t\t\t\t\t2018;\n\t\t\t\t\t55(2):\n\t\t\t\t\t216\u2013\n\t\t\t\t\t226.","DOI":"10.1177\/0004563217707783"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b33","doi-asserted-by":"crossref","unstructured":"Schrapp\n              A,\n            \n            \n              Fraissinet\n              F,\n            \n            \n              Hervouet\n              C,\n            \n            \n              Girot\n              H,\n            \n            \n              Brunel\n              V.\n            \n          \n          Biotin and high-sensitivity cardiac troponin T assay.\n\t\t\t\t\tBiochem Med (Zagreb).\n\t\t\t\t\t2018;\n\t\t\t\t\t28(3):\n\t\t\t\t\t030901.","DOI":"10.11613\/BM.2018.030901"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b34","doi-asserted-by":"crossref","unstructured":"Ardabilygazir\n              A,\n            \n            \n              Afshariyamchlou\n              S,\n            \n            \n              Mir\n              D,\n            \n            \n              Sachmechi\n              I.\n            \n          \n          Effect of high-dose biotin on thyroid function tests: case report and literature review.\n\t\t\t\t\tCureus.\n\t\t\t\t\t2018;\n\t\t\t\t\t10(6):\n\t\t\t\t\te2845.\n\t\t\t\t\tdoi:10.7759\/cureus.2845","DOI":"10.7759\/cureus.2845"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b35","doi-asserted-by":"crossref","unstructured":"Al-Salameh\n              A,\n            \n            \n              Becquemont\n              L,\n            \n            \n              Brailly-Tabard\n              S,\n            \n            \n              Aubourg\n              P,\n            \n            \n              Chanson\n              P.\n            \n          \n          A somewhat bizarre case of Graves disease due to vitamin treatment.\n\t\t\t\t\tJ Endocr Soc.\n\t\t\t\t\t2017;\n\t\t\t\t\t1(5):\n\t\t\t\t\t431\u2013\n\t\t\t\t\t435.","DOI":"10.1210\/js.2017-00054"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b36","doi-asserted-by":"crossref","unstructured":"Bowen\n              R,\n            \n            \n              Benavides\n              R,\n            \n            \n              Col\u00f3n-Franco\n              JM,\n            \n            et al.\n          \n          Best practices in mitigating the risk of biotin interference with laboratory testing\n          [published online\n          August\n          29,\n          2019].\n\t\t\t\t\tClin Biochem. doi:10.1016\/j.clinbiochem.2019.08.012","DOI":"10.1016\/j.clinbiochem.2019.08.012"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b37","doi-asserted-by":"crossref","unstructured":"Roffi\n              M,\n            \n            \n              Patrono\n              C,\n            \n            \n              Collet\n              J-P,\n            \n            et al.\n          \n          2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).\n\t\t\t\t\tEur Heart J.\n\t\t\t\t\t2016;\n\t\t\t\t\t37(3):\n\t\t\t\t\t267\u2013\n\t\t\t\t\t315.","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"2020090814512528900_i1543-2165-144-9-1108-b38","unstructured":"Roche Diagnostics GmbH.\n          Roche Elecsys method sheets.\n\t\t\t\t\tMannheim, Germany:\n\t\t\t\t\tRoche Diagnostics GmbH;\n\t\t\t\t\t2016\u20132019.\n\t\t\t\t\thttps:\/\/pim-eservices.roche.com\/eLD_SF\/gb\/en\/KeywordSearch. Accessed July 11, 2019."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b39","unstructured":"Roche Diagnostics GmbH.\n          Elecsys Troponin T hs [method sheet].\n\t\t\t\t\tMannheim, Germany:\n\t\t\t\t\tRoche Diagnostics GmbH;\n\t\t\t\t\t2019.\n\t\t\t\t\thttps:\/\/pim-eservices.roche.com\/eLD_SF\/de\/de\/Documents\/GetDocument?documentId=f7e2f5b6-2199-e911-f08c-00215a9b3428. Accessed July 15, 2019."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b40","unstructured":"Roche Diagnostics GmbH.\n          Elecsys TSH [method sheet].\n\t\t\t\t\tMannheim, Germany:\n\t\t\t\t\tRoche Diagnostics GmbH;\n\t\t\t\t\t2019.\n\t\t\t\t\thttps:\/\/pim-eservices.roche.com\/eLD_SF\/de\/de\/Documents\/GetDocument?documentId=501126e8-8b60-e911-6595-00215a9b3428. Accessed September 17, 2019."},{"key":"2020090814512528900_i1543-2165-144-9-1108-b41","unstructured":"Clinical and Laboratory Standards Institute.\n          \n            CLSI EP17 \u2013 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline\n          .\n\t\t\t\t\t2nd ed.Wayne, PA:\n\t\t\t\t\tCLSI;\n\t\t\t\t\t2012."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/9\/1108\/2580393\/i1543-2165-144-9-1108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/9\/1108\/2580393\/i1543-2165-144-9-1108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:41:29Z","timestamp":1764790889000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/9\/article-p1108.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,1,16]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2019-0425-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,16]]}}}